Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

INTRODUCTION: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. METHODS: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. RESULTS: The median age was 50.3...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:FRONTIERS IN IMMUNOLOGY 2023-03, Vol.14
Hauptverfasser: Ljungman, Per, Tridello, Gloria, Pinana, Jose Luis, Ciceri, Fabio, Sengeloev, Henrik, Kulagin, Alexander, Mielke, Stephan, Yegin, Zeynep Arzu, Collin, Matthew, Einardottir, Sigrun, Lepretre, Sophie Ducastelle, Maertens, Johan, Campos, Antonio, Metafuni, Elisabetta, Pichler, Herbert, Folber, Frantisek, Solano, Carlos, Nicholson, Emma, Yuksel, Meltem Kurt, Carlson, Kristina, Aguado, Beatriz, Besley, Caroline, Byrne, Jenny, Heras, Immaculada, Dignan, Fiona, Kroger, Nicolaus, Robin, Christine, Khan, Anjum, Lenhoff, Stig, Grassi, Anna, Dobsinska, Veronika, Miranda, Nuno, Jimenez, Maria-Jose, Yonal-Hindilerden, Ipek, Wilson, Keith, Averbuch, Dina, Cesaro, Simone, Xhaard, Alienor, Knelange, Nina, Styczynski, Jan, Mikulska, Malgorzata, de la Camara, Rafael
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:INTRODUCTION: COVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. METHODS: This study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. RESULTS: The median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p
ISSN:1664-3224
1664-3224